Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Emerson Lim, MD
Email
el2342@cumc.columbia.edu

Dr. Lim received his B.S. in Biomedical Engineering from Johns Hopkins University. He earned his medical degree at The New York Univeristy School of Medicine where he was Alpha Omega Alpha. He completed his residency in Internal Medicine, and fellowship in Hematology and Medical Oncology at Columbia Univeristy Medical Center. During that time he was awared a Post-doctoral Fellowship Clinical Research Grant from the Susan G. Komen Foundation and completed a Masters degree in Biostatistics at the Mailman School of Public Health.

Dr. Lim cares for patients with genitourinary cancers, including prostate, bladder, kidney, and testicular cancers. His current research interest, for which he was awarded a pilot grant from the Irving Institute for Clinical and Translational Research, is in prostate cancer imaging to detect prostate cancer and to determine its aggressiveness. He also actively participates in multicenter cooperative group clinical trials and is involved in developing investigator-initiated studies to evaluate novel therapeutic agents discovered in the lab and novel combinations of agents for treatment of genitourinary malignancies.


Clinical Studies Managed By Dr. Lim:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for patients with solid tumors using study drug ASP5878AstellasAAAP3615
Details[CLOSED] A study for patients with advanced cancer using study drug BAY 1251152BayerAAAQ4758
Details[CLOSED] A study for patients with muscle invasive bladder cancer (MIBC) using study drugs MEDI4736 and AZD4547AstraZenecaAAAQ4008
Details[CLOSED] A study for patients with advanced solid tumors using study drug BMS-986207Bristol-Myers SquibbAAAR0263
DetailsPhase I Assessment of AZD4635 as a Monotherapy and in Combination with Durvalumab in Patients with Advanced Solid MalignanciesAstraZeneca ABAAAR5156
DetailsMy Pathway: Study Evaluating Drug in Patients with Advanced Solid Tumors with Mutations or Gene Expression AbnormalitiesGenentech, Inc.AAAN9701
Details[CLOSED] Study of Drug in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Prostate CancerBayer HealthCare Pharmaceuticals Inc.AAAR0253
Details[CLOSED] Study for Patients with Urothelial Carcinoma that is Unresectable or Metastatic/RecurrentInovio Pharmaceuticals, Inc.AAAR5857
Details[CLOSED] Study of Drug in Patients with Renal Cell Carcinoma (RCC; Type of Kidney Cancer) after Nephrectomy (Removal of all or Part of Kidney)F. Hoffman- La Roche LtdAAAR1053
DetailsStudy of Drug in Patients with Advanced Solid Malignancies and LymphomaRgenix, Inc.AAAR3867
Details[CLOSED] FRACTION: Study of Drug Combinations in Patients with Advanced Renal Cell CarcinomaBMSAAAR5002
Details[CLOSED] Diffuse Optical Tomography in Prostate Cancer Detection and Risk Stratification - A Pilot StudyColumbia UniversityAAAL3709
DetailsStudy of Prostate Cancer Monitoring Using PyL and Blood-Based BiomarkersEmerson Lim, MDAAAR6032
DetailsStudy of COM701 Alone and in Combination in Patients with Advanced Solid Tumors (Breast Cancer, Ovarian Cancer, or Lung Cancer)Compugen Inc.AAAR9998
DetailsStudy of Chemotherapy alone, Chemotherapy plus Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder CancerBristol Myers SquibbAAAS0581
Details18F-DCFPyL PET/CT in Men with Prostate CancerNAAAAS1862
DetailsStudy of ASTX029 in Subjects With Advanced Solid TumorsAstex Pharmaceuticals, IncAAAS1827
DetailsA Study of JNJ-63898081 in Participants With Advanced Stage Solid TumorsJanssen Research & Development, LLCAAAS3847
DetailsStudy of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)NIHAAAS5647
DetailsStudy of TTX-030 Alone and in Combination with Pembrolizumab or Chemotherapy in Subjects with Lymphoma or Solid TUmor MalignanciesTizona TherapeuticsAAAS3111